SC
IRLA

Stempoint Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Stempoint Capital’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,696
Closed -$2.48M – 110
2025
Q4 		$2.48M Buy
+3,696
New +$1.86M 0.42% 53

Other funds holding IRLA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Stempoint Capital's IRLA Position: Q1 2026 in Review

Stempoint Capital sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 3,696 shares — an estimated $2.48M sold.

Stempoint Capital first reported a position in IRLA in Q4 2025 and held it in 1 quarter. The position peaked at $2.48M in Q4 2025. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • Stempoint Capital reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 3,696 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $2.48M.
  • Stempoint Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2025 and held it in 1 quarter.
  • Stempoint Capital's IRulya Therapeutics Inc. Common Stock position peaked at $2.48M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.